{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:15:38Z","timestamp":1794435338717,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-01959-8","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:37:01Z","timestamp":1738334221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Revisiting substance P in migraine: a methodological approach inspired by anti-CGRP and anti-PACAP success"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-5039","authenticated-orcid":false,"given":"Lanfranco","family":"Pellesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1805-1346","authenticated-orcid":false,"given":"Lars","family":"Edvinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"issue":"6","key":"1959_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14(6):338\u2013350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"1959_CR2","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/acn3.52119","volume":"11","author":"N Karsan","year":"2024","unstructured":"Karsan N, Edvinsson L, Vecsei L, Goadsby PJ (2024) Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders. Ann Clin Transl Neurol 11(7):1654\u20131668. https:\/\/doi.org\/10.1002\/acn3.52119","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"1959_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.peptides.2011.12.019","volume":"33","author":"B Tuka","year":"2012","unstructured":"Tuka B, Helyes Z, Markovics A, Bagoly T, N\u00e9meth J, M\u00e1rk L et al (2012) Peripheral and central alterations of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat in response to activation of the trigeminovascular system. Peptides 33(2):307\u2013316. https:\/\/doi.org\/10.1016\/j.peptides.2011.12.019","journal-title":"Peptides"},{"key":"1959_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3389\/fneur.2017.00745","volume":"8","author":"T K\u00f6rt\u00e9si","year":"2018","unstructured":"K\u00f6rt\u00e9si T, Tuka B, Tajti J, Bagoly T, F\u00fcl\u00f6p F, Helyes Z et al (2018) Kynurenic acid inhibits the electrical stimulation induced elevated pituitary adenylate cyclase-activating polypeptide expression in the TNC. Front Neurol 8:745. https:\/\/doi.org\/10.3389\/fneur.2017.00745","journal-title":"Front Neurol"},{"issue":"1","key":"1959_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/14728214.2024.2317778","volume":"29","author":"L Pellesi","year":"2024","unstructured":"Pellesi L, Ashina M, Martelletti P (2024) Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention. Expert Opin Emerg Drugs 29(1):57\u201364. https:\/\/doi.org\/10.1080\/14728214.2024.2317778","journal-title":"Expert Opin Emerg Drugs"},{"issue":"9","key":"1959_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJMoa2314577","volume":"391","author":"M Ashina","year":"2024","unstructured":"Ashina M, Phul R, Khodaie M, L\u00f6f E, Florea I (2024) A monoclonal antibody to PACAP for Migraine Prevention. N Engl J Med 391(9):800\u2013809. https:\/\/doi.org\/10.1056\/NEJMoa2314577","journal-title":"N Engl J Med"},{"issue":"1","key":"1959_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0304-3940(85)90296-4","volume":"62","author":"R Uddman","year":"1985","unstructured":"Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J (1985) Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 62(1):131\u2013136. https:\/\/doi.org\/10.1016\/0304-3940(85)90296-4","journal-title":"Neurosci Lett"},{"key":"1959_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1113\/jphysiol.1981.sp013862","volume":"318","author":"L Edvinsson","year":"1981","unstructured":"Edvinsson L, McCulloch J, Uddman R (1981) Substance P: immunohistochemical localization and effect upon cat pial arteries in vitro and in situ. J Physiol 318:251\u2013258. https:\/\/doi.org\/10.1113\/jphysiol.1981.sp013862","journal-title":"J Physiol"},{"key":"1959_CR9","doi-asserted-by":"publisher","first-page":"174480692110594","DOI":"10.1177\/17448069211059400","volume":"17","author":"JC Edvinsson","year":"2021","unstructured":"Edvinsson JC, Reducha PV, Sheykhzade M, Warfvinge K, Haanes KA, Edvinsson L (2021) Neurokinins and their receptors in the rat trigeminal system: Differential localization and release with implications for migraine pain. Mol Pain 17:17448069211059400. https:\/\/doi.org\/10.1177\/17448069211059400","journal-title":"Mol Pain"},{"issue":"6 Suppl 3","key":"1959_CR10","first-page":"S16","volume":"43","author":"MA Moskowitz","year":"1993","unstructured":"Moskowitz MA (1993) Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 43(6 Suppl 3):S16\u2013S20","journal-title":"Neurology"},{"issue":"2","key":"1959_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/s0006-8993(00)02440-9","volume":"871","author":"JK Neubert","year":"2000","unstructured":"Neubert JK, Maidment NT, Matsuka Y, Adelson DW, Kruger L, Spigelman I (2000) Inflammation-induced changes in primary afferent-evoked release of substance P within trigeminal ganglia in vivo. Brain Res 871(2):181\u2013191. https:\/\/doi.org\/10.1016\/s0006-8993(00)02440-9","journal-title":"Brain Res"},{"issue":"7","key":"1959_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1046\/j.1468-2982.1997.1707785.x","volume":"17","author":"DJ Goldstein","year":"1997","unstructured":"Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT (1997) Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 17(7):785\u2013790. https:\/\/doi.org\/10.1046\/j.1468-2982.1997.1707785.x","journal-title":"Cephalalgia"},{"issue":"3","key":"1959_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1046\/j.1468-2982.2003.00496.x","volume":"23","author":"HC Diener","year":"2003","unstructured":"Diener HC, RPR100893 Study Group (2003) RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 23(3):183\u2013185. https:\/\/doi.org\/10.1046\/j.1468-2982.2003.00496.x","journal-title":"Cephalalgia"},{"issue":"1","key":"1959_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s10194-024-01796-1","volume":"25","author":"J Olesen","year":"2024","unstructured":"Olesen J (2024) Provocation of attacks to discover migraine signaling mechanisms and new drug targets: early history and future perspectives - a narrative review. J Headache Pain 25(1):105. https:\/\/doi.org\/10.1186\/s10194-024-01796-1","journal-title":"J Headache Pain"},{"key":"1959_CR15","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International classification of Headache disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"issue":"12","key":"1959_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrneurol.2017.137","volume":"13","author":"M Ashina","year":"2017","unstructured":"Ashina M, Hansen JM, \u00c1 Dunga BO, Olesen J (2017) Human models of migraine - short-term pain for long-term gain. Nat Rev Neurol 13(12):713\u2013724","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1959_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2307\/2528039","volume":"24","author":"OS Miettinen","year":"1968","unstructured":"Miettinen OS (1968) The matched pairs design in the case of all-or-none responses. Biometrics 24(2):339\u2013352","journal-title":"Biometrics"},{"issue":"4","key":"1959_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3109\/00365528609015169","volume":"21","author":"S Schaffalitzky De Muckadell","year":"1986","unstructured":"Schaffalitzky De Muckadell S OB, Aggestrup, Stentoft P (1986) Flushing and plasma substance P concentration during infusion of synthetic substance P in normal man. Scand J Gastroenterol 21(4):498\u2013502. https:\/\/doi.org\/10.3109\/00365528609015169","journal-title":"Scand J Gastroenterol"},{"issue":"10283","key":"1959_CR19","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Terwindt GM, Al-Karagholi MA, de Boer I, Lee MJ, Hay DL et al (2021) Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397(10283):1496\u20131504. https:\/\/doi.org\/10.1016\/S0140-6736(20)32162-0","journal-title":"Lancet"},{"issue":"1","key":"1959_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-023-01567-4","volume":"24","author":"L Al-Hassany","year":"2023","unstructured":"Al-Hassany L, Boucherie DM, Creeney H, van Drie RWA, Farham F, Favaretto S et al (2023) Future targets for migraine treatment beyond CGRP. J Headache Pain 24(1):76. https:\/\/doi.org\/10.1186\/s10194-023-01567-4","journal-title":"J Headache Pain"},{"issue":"3","key":"1959_CR21","first-page":"230","volume":"1","author":"R Uddman","year":"1989","unstructured":"Uddman R, Edvinsson L (1989) Neuropeptides in the cerebral circulation. Cerebrovasc Brain Metab Rev 1(3):230\u2013252","journal-title":"Cerebrovasc Brain Metab Rev"},{"issue":"6","key":"1959_CR22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/bja\/aeg572","volume":"90","author":"BM Fusco","year":"2003","unstructured":"Fusco BM, Barzoi G, Agr\u00f2 F (2003) Repeated intranasal capsaicin applications to treat chronic migraine. Br J Anaesth 90(6):812. https:\/\/doi.org\/10.1093\/bja\/aeg572","journal-title":"Br J Anaesth"},{"issue":"11","key":"1959_CR23","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41582-024-01011-4","volume":"20","author":"H Ashina","year":"2024","unstructured":"Ashina H, Christensen RH, Hay DL, Pradhan AA, Hoffmann J, Reglodi D et al (2024) Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine. Nat Rev Neurol 20(11):660\u2013670. https:\/\/doi.org\/10.1038\/s41582-024-01011-4","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"1959_CR24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0009-9236(98)90140-0","volume":"64","author":"RA Dionne","year":"1998","unstructured":"Dionne RA, Max MB, Gordon SM, Parada S, Sang C, Gracely RH et al (1998) The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 64(5):562\u2013568. https:\/\/doi.org\/10.1016\/S0009-9236(98)90140-0","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1959_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ejpain.2005.08.001","volume":"10","author":"SH Sindrup","year":"2006","unstructured":"Sindrup SH, Graf A, Sfikas N (2006) The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur J Pain 10(6):567\u2013571. https:\/\/doi.org\/10.1016\/j.ejpain.2005.08.001","journal-title":"Eur J Pain"},{"issue":"1","key":"1959_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-018-0909-4","volume":"19","author":"AL Vollesen","year":"2018","unstructured":"Vollesen AL, Benemei S, Cortese F, Labastida-Ram\u00edrez A, Marchese F, Pellesi L et al (2018) Migraine and cluster headache - the common link. J Headache Pain 19(1):89. https:\/\/doi.org\/10.1186\/s10194-018-0909-4","journal-title":"J Headache Pain"},{"issue":"1","key":"1959_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2340\/00015555-2780","volume":"98","author":"T Ohanyan","year":"2018","unstructured":"Ohanyan T, Schoepke N, Eirefelt S, Hoey G, Koopmann W, Hawro T et al (2018) Role of Substance P and its receptor neurokinin 1 in chronic Prurigo: a Randomized, Proof-of-Concept, controlled trial with topical aprepitant. Acta Derm Venereol 98(1):26\u201331. https:\/\/doi.org\/10.2340\/00015555-2780","journal-title":"Acta Derm Venereol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-01959-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-01959-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-01959-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:37:03Z","timestamp":1738334223000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-01959-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1959"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-01959-8","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lanfranco Pellesi serves as member of Editorial Board of The Journal of Headache and Pain, BMC Neurology and European Journal of Medical Research. In addition, Lanfranco Pellesi is editor-in-training for Clinical and Translational Science. Lars Edvinsson has received research grants and received speaker support (fees and travel) from Amgen Inc, Novartis, Lundbeck, and AbbVie regarding basic research on monoclonal antibodies and gepants to understand their sites of action.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}